BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 24201979)

  • 1. Ruthenium(II) and osmium(II) 1,2,3-triazolylidene organometallics: a preliminary investigation into the biological activity of 'click' carbene complexes.
    Kilpin KJ; Crot S; Riedel T; Kitchen JA; Dyson PJ
    Dalton Trans; 2014 Jan; 43(3):1443-8. PubMed ID: 24201979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences.
    Hanif M; Nazarov AA; Hartinger CG; Kandioller W; Jakupec MA; Arion VB; Dyson PJ; Keppler BK
    Dalton Trans; 2010 Aug; 39(31):7345-52. PubMed ID: 20601976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipophilicity-dependent ruthenium N-heterocyclic carbene complexes as potential anticancer agents.
    Lv G; Guo L; Qiu L; Yang H; Wang T; Liu H; Lin J
    Dalton Trans; 2015 Apr; 44(16):7324-31. PubMed ID: 25797411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tuning the reactivity of osmium(II) and ruthenium(II) arene complexes under physiological conditions.
    Peacock AF; Habtemariam A; Fernández R; Walland V; Fabbiani FP; Parsons S; Aird RE; Jodrell DI; Sadler PJ
    J Am Chem Soc; 2006 Feb; 128(5):1739-48. PubMed ID: 16448150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruthenium(II) arene PTA (RAPTA) complexes: impact of enantiomerically pure chiral ligands.
    Kilpin KJ; Cammack SM; Clavel CM; Dyson PJ
    Dalton Trans; 2013 Feb; 42(6):2008-14. PubMed ID: 23187957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates.
    Riedl CA; Flocke LS; Hejl M; Roller A; Klose MH; Jakupec MA; Kandioller W; Keppler BK
    Inorg Chem; 2017 Jan; 56(1):528-541. PubMed ID: 27996251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.
    Hanif M; Meier SM; Kandioller W; Bytzek A; Hejl M; Hartinger CG; Nazarov AA; Arion VB; Jakupec MA; Dyson PJ; Keppler BK
    J Inorg Biochem; 2011 Feb; 105(2):224-31. PubMed ID: 21194622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From Catalysis to Cancer: Toward Structure-Activity Relationships for Benzimidazol-2-ylidene-Derived N-Heterocyclic-Carbene Complexes as Anticancer Agents.
    Lam NYS; Truong D; Burmeister H; Babak MV; Holtkamp HU; Movassaghi S; Ayine-Tora DM; Zafar A; Kubanik M; Oehninger L; Söhnel T; Reynisson J; Jamieson SMF; Gaiddon C; Ott I; Hartinger CG
    Inorg Chem; 2018 Nov; 57(22):14427-14434. PubMed ID: 30406647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selenoquinones stabilized by ruthenium(II) arene complexes: synthesis, structure, and cytotoxicity.
    Dubarle-Offner J; Clavel CM; Gontard G; Dyson PJ; Amouri H
    Chemistry; 2014 May; 20(19):5795-801. PubMed ID: 24668791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of RAPTA moieties on the antiproliferative activity of peripheral-functionalised poly(salicylaldiminato) metallodendrimers.
    Govender P; Sudding LC; Clavel CM; Dyson PJ; Therrien B; Smith GS
    Dalton Trans; 2013 Jan; 42(4):1267-77. PubMed ID: 23143220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339.
    Büchel GE; Kossatz S; Sadique A; Rapta P; Zalibera M; Bucinsky L; Komorovsky S; Telser J; Eppinger J; Reiner T; Arion VB
    Dalton Trans; 2017 Sep; 46(35):11925-11941. PubMed ID: 28850133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly active neutral ruthenium(II) arene complexes: synthesis, characterization, and investigation of their anticancer properties.
    Ludwig G; Kaluđerović GN; Bette M; Block M; Paschke R; Steinborn D
    J Inorg Biochem; 2012 Aug; 113():77-82. PubMed ID: 22698819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amide linkage isomerism as an activity switch for organometallic osmium and ruthenium anticancer complexes.
    van Rijt SH; Hebden AJ; Amaresekera T; Deeth RJ; Clarkson GJ; Parsons S; McGowan PC; Sadler PJ
    J Med Chem; 2009 Dec; 52(23):7753-64. PubMed ID: 19791745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapeutic Activities of New η
    Ywaya DO; Ibrahim H; Friedrich HB; Bala MD; Soobramoney L; Daniels A; Singh M
    Molecules; 2024 Feb; 29(5):. PubMed ID: 38474456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-Inflammatory Oxicams as Multi-donor Ligand Systems: pH- and Solvent-Dependent Coordination Modes of Meloxicam and Piroxicam to Ru and Os.
    Aman F; Hanif M; Kubanik M; Ashraf A; Söhnel T; Jamieson SM; Siddiqui WA; Hartinger CG
    Chemistry; 2017 Apr; 23(20):4893-4902. PubMed ID: 28198061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruthenium- and osmium-arene-based paullones bearing a TEMPO free-radical unit as potential anticancer drugs.
    Arion VB; Dobrov A; Göschl S; Jakupec MA; Keppler BK; Rapta P
    Chem Commun (Camb); 2012 Sep; 48(68):8559-61. PubMed ID: 22797078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruthenium(II/III)-based compounds with encouraging antiproliferative activity against non-small-cell lung cancer.
    Nagy EM; Pettenuzzo A; Boscutti G; Marchiò L; Dalla Via L; Fregona D
    Chemistry; 2012 Nov; 18(45):14464-72. PubMed ID: 23012112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defining the Anti-Cancer Activity of Tricarbonyl Rhenium Complexes: Induction of G2/M Cell Cycle Arrest and Blockade of Aurora-A Kinase Phosphorylation.
    Simpson PV; Casari I; Paternoster S; Skelton BW; Falasca M; Massi M
    Chemistry; 2017 May; 23(27):6518-6521. PubMed ID: 28337805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cationic arene ruthenium(II) complexes with chelating P-functionalized alkyl phenyl sulfide and sulfoxide ligands as potent anticancer agents.
    Ludwig G; Kaluđerović GN; Rüffer T; Bette M; Korb M; Block M; Paschke R; Lang H; Steinborn D
    Dalton Trans; 2013 Mar; 42(11):3771-4. PubMed ID: 23340605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of the structural determinants for anticancer activity of a ruthenium arene peptide conjugate.
    Meier SM; Novak M; Kandioller W; Jakupec MA; Arion VB; Metzler-Nolte N; Keppler BK; Hartinger CG
    Chemistry; 2013 Jul; 19(28):9297-307. PubMed ID: 23712572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.